MEB-1170
MEB-1170 is an oral analgesic to solve the opiod crisis
indication for meb-1170
- Replacement of Schedule II opioids in pain management (e.g. Oxycodone)
- Treat moderate-to-severe pain
- Estimated once a day
- Home-use pain management after surgery and management of chronic pain conditions
MEB-1170 Treats pain without opioid adverse effects
Active in 3 Rodent Pain Models
No Respiratory Depression
-
- Oral with long half-life
- As efficacious as morphine
- Confirmed in 3 in vivo pain models (Formalin Induced Pain, Post Incisional Pain, Tail Flick)
-
- Acute and chronic oral dosing
- Normal pO2, pCO2, pH
- Normal respiratory drive (Respiratory Rate, Minute Volume, Tidal Volume)
Devoid of Other Serious Issues Seen in Marketed Opioids
-
- Does not produce tolerance to analgesia
- Does not cause constipation
- Does not cause sedation
- No toxicity seen in observational reads
MEB-1170 Shows no abuse potential in FDA required preclinical models for CNS Drugs
No Drug Seeking Behavior
No Self-Administration
Minimal Withdrawal
Drug Discrimination
MEB-1170 has the potential to prevent and to treat opioid abuse in patients undergoing pain therapy
Rats abusing Oxycodone do not abuse MEB-1170
Rats using MEB-1170 do not abuse Oxycodone
